Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review
{{output}}
Introduction: Hyperammonemia is a potential adverse effect of valproic acid (VPA) therapy, which is often asymptomatic but can lead to severe, life-threatening encephalopathy. Carnitine deficiency due to VPA is the proposed mecha... ...
